Acadian Asset Management
ENVB icon

Acadian Asset Management’s Enveric Biosciences ENVB Stock Holding History

Acadian Asset Management’s Portfolio ENVB Stock Details ENVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1
Closed – – 1786
2024
Q1 		$0 Hold
1
– – ﹤0.01% 1622
2023
Q4 		$0 Sell
1
-24
-96% -$7.37K ﹤0.01% 1703
2023
Q3 		$10K Hold
25
– – ﹤0.01% 1591
2023
Q2 		$15K Buy
+25
New +$12.2K ﹤0.01% 1662
2019
Q1 		– Hold
0
– -$5K – 1978
2018
Q4 		– Hold
0
– – – 1662

Other funds holding ENVB

AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Acadian Asset Management's ENVB Position: Q2 2024 in Review

Acadian Asset Management sold out of Enveric Biosciences (ENVB) in Q2 2024, closing a stake of 1 share.

Acadian Asset Management first reported a position in ENVB in Q2 2023 and held it in 4 quarters. The position peaked at $15K in Q2 2023. 13 funds tracked by Wall St. Rank hold ENVB as of Q2 2024.

  • Acadian Asset Management reported no remaining Enveric Biosciences position as of Q2 2024 after selling out during the quarter.
  • Acadian Asset Management sold 1 Enveric Biosciences share in Q2 2024.
  • Acadian Asset Management first reported a position in Enveric Biosciences in Q2 2023 and held it in 4 quarters.
  • Acadian Asset Management's Enveric Biosciences position peaked at $15K in Q2 2023.
  • 13 funds tracked by Wall St. Rank held Enveric Biosciences as of Q2 2024.

Based on Acadian Asset Management's 13F filing for Q2 2024, filed 6 Aug 2024.